|From Yissum's President & CEO|
based on breakthrough Hebrew University science have turned into reality.
The past year has been a year of achievements at Yissum, as new business initiatives
First, I am proud to inform our colleagues and friends that Yissum has recently founded Integra Holdings, a new holding company focused on biopharmaceutical companies that are based on inventions of Hebrew University scientists and researchers. We have been successful in raising $7 million for this endeavor, which is directed at biotech companies with products mostly in clinical stages of development. I believe that this new initiative will greatly enhance the commercial success of biotech inventions originating from the Hebrew University.
The past year has also been a year of continued progress, in which we signed 70 license and option to license agreements and founded seven new startup companies in a variety of fields, including biopharmaceuticals, agriculture and cleantech, three of which are part of the Ministry of Industry, Trade and Labor's Technological Incubators Program. We have also processed approximately 150 new inventions by Hebrew University’s researchers. Furthermore, during 2012 we have begun providing our patenting and commercial expertise also to clinicians at Shaare Zedek Hospital, turning Yissum into the only technology transfer company in Israel that provides services both to a university and a hospital.
Over $14 million were made available this year to our scientists through research collaborations with large companies. In addition, during 2012, we signed additional framework agreements with leading corporations such as Coca-Cola and Intel, and continued our long-term research partnerships with Google, Roche, General Motors and Procter & Gamble.
We would like to encourage Hebrew University researchers to continue to apply for the various financial funds that Yissum offers. Over the past year, 22 new projects received Baby Seed grants to support their research. We were also highly successful in obtaining Chief Scientist grants: 12 Kamin projects and 10 Nofar applications were approved.
Finally, I would like to welcome aboard Dr. Aharon Schwartz, as Yissum’s new Chairman of the Board, as well as three new distinguished board members: Dr. Judith Richter, Gideon Federmann and Assaf Harlap. We also welcome Dr. Michal Levy, who replaced Ziv Shomroni as Yissum’s VP, Head of Business Development Agriculture & Environment.
I wish us all a future of innovation and creation in which we will continue and enhance the fruitful collaboration between scientific innovation and commercial success.
Yaacov Michlin, CEO
and the Yissum Team
Morflora develops a bio-based generic solution for introducing traits into plants and seeds, for plant and seed enhancement as well as for protection from a wide variety of diseases.
|Start Up Spotlight: Morflora|
The company targets mainly the seed treatment market, with plant protection and enhancement solutions that reduce dependence on chemical treatments in plants, and increase global crop yield. Morflora's core technology, TraitUP™ is patent-pending and was developed at the Hebrew University by Prof. Haim Rabinowitch and Prof. Ilan Sela.
Become a Member of Yissum's Technology Database
Receive regular updates on new technologies in areas of interest to you.
Visit our new website
Check out Yissum’s shop of technologies.
On October 31st, Yissum announced the inception of its subsidiary, Integra Holdings, a holding company focusing on biopharmaceutical companies based on inventions of researchers from the Hebrew University. In addition, Integra Holdings announced the closing of a U.S. $7.0 million first round of financing. The funds raised will be used not only to advance Integra's existing portfolio companies but also, with Yissum's mediation, to invest in additional promising applicable research projects originating from the Hebrew University.
|Yissum Announces Formation of Integra Holdings|
Integra Holdings focuses on biotech companies with products mostly in clinical stages of development. Integra Holdings’ robust portfolio is currently composed of companies operating in diverse therapeutic fields of high industry interest ranging from oncology to Alzheimer’s disease, and from infectious diseases to allergies, and includes four Phase II companies, three Phase I companies and one company in pre-clinical stages of development.
The companies are: Algen, Atox Bio, Avraham Pharmaceuticals, Doxocure, LipoCure, Lipomedix, Omer Therapeutics and Tiltan Pharma.
Read more of Integra Holdings.
|Yissum Spin Offs In the News|
YISSUM SPIN OFF ATOX BIO REPORTS POSITIVE TISSUE INFECTION TRIAL RESULTS
The company, which was lately granted FDA Fast Track designation for its lead product, reported positive clinical trial results of the drug for the treatment of necrotizing soft tissue infections.
TILTAN PHARMA ANNOUNCES ENROLLMENT OF FIRST U.S. PATIENT IN A PHASE 2 CLINICAL TRIAL OF TL-118, ANTI-ANGIOGENIC TREATMENT FOR METASTATIC PANCREATIC CANCER
Tiltan Pharma is one of the portfolio companies of Integra Holdings, a biopharmaceutical holding company founded by Yissum, the technology transfer company of the Hebrew University of Jerusalem.
Over three hundred industry and government leaders attended the first meeting of the Israel Tech Transfer Organization (ITTN)-, that took place on June 11th, in Tel Aviv.
|The Annual Conference of the ITTN|
All enjoyed a tour de force by the leading tech transfer companies in Israel, portraying successes and products on market that originate from academia, as well as promising new startups.
Yaacov Michlin was recently appointed Co-Chairman of the ITTN.
Take a look at the new ITTN movie.
INTEL INTRODUCES THE FUTURE WITH LEARNNG COMPUTERS
Intel Corp is launching research in Israel into technology that mimics the human brain and develops devices that learn about their user. The research, to be carried out by the Intel Collaborative Research Institute for Computational Intelligence along with specialists from the Technion in Haifa and the Hebrew University in Jerusalem, is aimed at enabling new applications, such as small, wearable computers that can enhance daily life.
YISSUM INTRODUCES A PIONEERING VACCINE AGAINST CANINE MONOCYTIC EHRLICHIOSIS, A FATAL TICK-BORNE DISEASE IN DOGS
Results showing the effectiveness of the vaccine in dogs were recently published in the journal Vaccine
MERCK EXPANDS CAPABILITIES ON NOVEL MATERIALS FOR DISPLAY AND LIGHTING BY INVESTING IN YISSUM SPIN OFF QLIGHT NANOTECH
Merck announced today that within the scope of a capital increase by the Israeli start-up company QLight Nanotech, it is acquiring an interest in the Jerusalem-based company.
YISSUM INTRODUCES A NOVEL METHOD FOR IMPROVING FISH FARMING
The technology, which was presented at Agritech Israel 2012, enables better control over fish reproduction cycle, increasing spawning and fish size.
THE FACES OF GENIUS
New Hebrew University portrait exhibition spotlights the researchers whose bright ideas led to global products that improve quality of life. “If Israel is the start-up nation, then the Hebrew University is the start-up of the start-up nation,” said Hebrew University president Prof. Menahem Ben-Sasson at the opening. “So far, the university [through its tech-transfer company Yissum Research Development] has registered approximately 7,000 patents protecting roughly 2,000 developments and inventions, and founded 72 companies based on some of those inventions.”
HIV PEPTIDE FOR CANCER TREATMENT
Hebrew University medical researchers find a tiny peptide encoded by the HIV virus that could hold the key to making cancer therapies more successful.
THE RESEARCHERS THAT PROLONG PLANT'S LIFE [HEBREW]
Five researchers at the Hebrew University's Faculty of Agriculture reach commercial success through Yissum, the university's technology transfer company.
Hundreds of technologies in various fields are available at Yissum’s website.
Here is but a small selection:
ENHANCED STORAGE AND TRANSPORTATION OF HYDROGEN FOR FUEL
Prof. Yoel Sasson
Efficient, easily reversible process for producing energy for vehicles and homes
SPLICING FACTOR ACTIVITY FOR DETECTING AND TREATING CANCER
Dr. Rotem Karni
Splicing factor levels predict patient prognosis and indicate drug efficacy
MOLECULAR BREEDING SCHEME FOR DROUGHT-RESISTANT COTTON
Prof. Yehoshua Saranga
Improving drought resistance in most popular commercial species